Human antibody polyreactivity is governed primarily by the heavy-chain complementarity-determining regions.

Autor: Chen HT; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA., Zhang Y; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA., Huang J; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA., Sawant M; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA., Smith MD; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA., Rajagopal N; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA., Desai AA; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA., Makowski E; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA., Licari G; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA., Xie Y; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA., Marlow MS; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA., Kumar S; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA., Tessier PM; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: ptessier@umich.edu.

Publikováno v: Cell reports [Cell Rep] 2024 Oct 22; Vol. 43 (10), pp. 114801. Date of Electronic Publication: 2024 Oct 10.

SPORE VIABILITY OF FERN SPECIES OF THE GENERA AMAUROPELTA, BLECHNUM, AND PHYSEMATIUM FROM CENTRAL ARGENTINA AFTER LOW TEMPERATURE STORAGE.

Autor: Luz Martinenco, M.¹, Arana, Marcelo D.^2,3, Luján Luna, M.¹ lujanluna@fcnym.unlp.edu.ar

Publikováno v: Boletín de la Sociedad Argentina de Botánica. sep2024, Vol. 59 Issue 3, p299-309. 11p.

An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence.

Autor: Lee CH; Department of Chemical Engineering, University of Texas at Austin, Austin, TX, USA., Kang TH; Department of Chemical Engineering, University of Texas at Austin, Austin, TX, USA.; Department of Applied Chemistry, Kookmin University, Seoul, Republic of Korea., Godon O; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERMF-75015, Paris, France., Watanabe M; Department of Chemical Engineering, University of Texas at Austin, Austin, TX, USA., Delidakis G; Department of Chemical Engineering, University of Texas at Austin, Austin, TX, USA., Gillis CM; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERMF-75015, Paris, France., Sterlin D; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERMF-75015, Paris, France., Hardy D; Experimental Neuropathology Unit, Infection and Epidemiology Department, Institut Pasteur, 25, rue du Docteur Roux, 75015, Paris, France., Cogné M; Limoges University, Limoges, France., Macdonald LE; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Murphy AJ; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Tu N; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Lee J; Thayer School of Engineering, Dartmouth College, Hanover, NH, USA., McDaniel JR; Department of Chemical Engineering, University of Texas at Austin, Austin, TX, USA., Makowski E; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA., Tessier PM; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA.; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA., Meyer AS; Department of Bioengineering, University of California at Los Angeles, Los Angeles, CA, USA., Bruhns P; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERMF-75015, Paris, France. bruhns@pasteur.fr., Georgiou G; Department of Chemical Engineering, University of Texas at Austin, Austin, TX, USA. gg@che.utexas.edu.; Department of Molecular Bioscience, University of Texas at Austin, Austin, TX, USA. gg@che.utexas.edu.; Department of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA. gg@che.utexas.edu.

Publikováno v: Nature communications [Nat Commun] 2019 Nov 06; Vol. 10 (1), pp. 5031. Date of Electronic Publication: 2019 Nov 06.

Endometrial carcinoma: clinical-pathologic comparison of cases in postmenopausal women receiving and not receiving exogenous estrogens.

Autor: Silverberg, Steven G., Mullen, Dennis, Faraci, Jack A., Makowski, Edgar L., Miller, Alexander, Finch, Jack L., Sutherland, Jeffrey V., Silverberg, S G, Mullen, D, Faraci, J A, Makowski, E L, Miller, A, Finch, J L, Sutherland, J V

Publikováno v: Cancer (0008543X); Jun1980, Vol. 45 Issue 12, p3018-3026, 9p

Optimization of therapeutic antibodies for reduced self-association and non-specific binding via interpretable machine learning.

Autor: Makowski EK; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA., Wang T; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA., Zupancic JM; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA., Huang J; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA., Wu L; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA., Schardt JS; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA., De Groot AS; University of Georgia, Athens, GA, USA., Elkins SL; EpiVax, Inc., Providence, RI, USA., Martin WD; EpiVax, Inc., Providence, RI, USA., Tessier PM; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA. ptessier@umich.edu.; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA. ptessier@umich.edu.; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA. ptessier@umich.edu.; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA. ptessier@umich.edu.

Publikováno v: Nature biomedical engineering [Nat Biomed Eng] 2024 Jan; Vol. 8 (1), pp. 45-56. Date of Electronic Publication: 2023 Sep 04.